I'm hoping it jumps back to $9 immediately and returns to $12-$13 over the next month or two. It could definitely get back to $15 when we get close to the ACTIV-5 finishing. The next catalyst that I am awaiting is to hear that the ACTIV-5 trial has enrolled 300 patients. The DSMB will be doing interim analysis for efficacy at that point and could even recommend an EUA at that time. Winter is coming. There still isn't an effective treatment available for newly hospitalized patients.